دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction
Jawad H. Butt, MD, a,b Toru Kondo, MD, PH D, a Pardeep S. Jhund, MBC H B, MS C, P HD, a Josep Comin-Colet, MD, c Rudolf A. de Boer, MD, PHD, d Akshai S. Desai, MD, MPH,e Adrian F. Hernandez, MD,f Silvio E. Inzucchi, MD, g Stefan P. Janssens, MD,h Mikhail N. Kosiborod, MD, i Carolyn S.P. Lam, MD, j Anna Maria Langkilde, MD, PHD, k Daniel Lindholm, MD, PHD, k Felipe Martinez, MD,l Magnus Petersson, MD, P HD, k Sanjiv J. Shah, MD, m Jorge Thierer, MD,n Muthiah Vaduganathan, MD, MPH,o Subodh Verma, MD,p Ulrica Wilderäng, PHD, k Brian L. Claggett, PH D, o Scott D. Solomon, MD, o John J.V. McMurray, MD
doi : 10.1016/j.jacc.2022.08.718
Volume 80, Issue 18, 1 November 2022, Pages 1705-1717
Atrial fibrillation (AF) is common in heart failure (HF), is associated with worse outcomes compared with sinus rhythm, and may modify the effects of therapy.
Gliflozins and Atrial Fibrillation∗
Ramon Corbalan, MD, Mónica Acevedo, MD
doi : 10.1016/j.jacc.2022.08.746
Volume 80, Issue 18, 1 November 2022, Pages 1718-1720
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria
Ashish Sarraju, MD, a George Bakris, MD, b Christopher P. Cannon, MD, c David Cherney, PHD, d C.V. Damaraju, P HD, e Gemma A. Figtree, P HD, f,g,h Jagadish Gogate, P HD, e Tom Greene, PH D, i Hiddo J.L. Heerspink, PH D, PHARMD, g,j James L. Januzzi, J R, MD,k Bruce Neal, P HD, g,l Meg J. Jardine, PHD, g,m,n Jaime Blais, PHD, e Mikhail Kosiborod, MD,g,o Adeera Levin, MD, p Ildiko Lingvay, MD, q Matthew R. Weir, MD,r Vlado Perkovic, P HD, g,s Kenneth W. Mahaffey, MD
doi : 10.1016/j.jacc.2022.08.772
Volume 80, Issue 18, 1 November 2022, Pages 1721-1731
People with type 2 diabetes mellitus (T2DM) have elevated cardiovascular (CV) risk, including for hospitalization for heart failure (HHF). Canagliflozin reduced CV and kidney events in patients with T2DM and high CV risk or nephropathy in the CANVAS (CANagliflozin cardioVascular Assessment Study) Program and the CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial.
Heart Failure and Kidney Disease in Type 2 Diabetes: 2 Sides of the Same Coin∗
Faiez Zannad, MD, PHD
doi : 10.1016/j.jacc.2022.08.773
Volume 80, Issue 18, 1 November 2022, Pages 1732-1734
Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes
Gorav Batra, MD, PH D, a,b Johan Lindbäck, MSC ,b Richard C. Becker, MD, c Robert A. Harrington, MD, d Claes Held, MD, PHD, a,b Stefan K. James, MD, P HD, a,b Tibor Kempf, MD, e Renato D. Lopes, MD, P HD, f Kenneth W. Mahaffey, MD, g Philippe Gabriel Steg, MD, h Robert F. Storey, MD, DM, i Eva Swahn, MD, PH D, j Kai C. Wollert, MD, e Agneta Siegbahn, MD, PHD, b,k Lars Wallentin, MD, PHD
doi : 10.1016/j.jacc.2022.08.767
Volume 80, Issue 18, 1 November 2022, Pages 1735-1747
In patients with acute coronary syndrome (ACS), there is residual and variable risk of recurrent ischemic events.
Ischemic Risk Prediction Scores: Practice-Changing or Just Practice?∗
Serge Korjian, MD, Robert W. Yeh, MD, MS C, Donald E. Cutlip, MD
doi : 10.1016/j.jacc.2022.08.766
Volume 80, Issue 18, 1 November 2022, Pages 1748-1750
Relationship of Circulating Vegetable Omega-3 to Prognosis in Patients With Heart Failure
Iolanda Lázaro, PHD, a Josep Lupón, MD, P HD, b,c,d Germán Cediel, MD, PHD, b,c Pau Codina, MD, PHD, b,c Montserrat Fitó, MD, PH D, a,e Mar Domingo, MD, PHD, b,c Evelyn Santiago-Vacas, MD, PHD, b,c Elisabet Zamora, MD, P HD, b,c,d Aleix Sala-Vila, P HARMD, PH D, a,f Antoni Bayés-GenÃs, MD, P HD b,
doi : 10.1016/j.jacc.2022.08.771
Volume 80, Issue 18, 1 November 2022, Pages 1751-1758
There is an urgent need for cost-effective strategies to promote quality of life in patients with heart failure (HF). Several studies reported benefits in HF prognosis for marine omega-3 fatty acids and plant-based dietary patterns.
Circulating Plant-Based Omega-3 in Heart Failure: A Prognostic Marker or a Therapeutic Target?∗
Abdallah Al-Mohammad, MD
doi : 10.1016/j.jacc.2022.09.001
Volume 80, Issue 18, 1 November 2022, Pages 1759-1761
Eliminating Disparities in Cardiovascular Disease for Black Women: JACC Review Topic of the Week
Modele O. Ogunniyi, MD, MPH,a,b Zainab Mahmoud, MD, c Yvonne Commodore-Mensah, RN, MHS, PH D, d,e Jerome L. Fleg, MD,f Yetunde A. Fatade, MD, MPH,g Odayme Quesada, MD, h,i Niti R. Aggarwal, MD, j Deirdre J. Mattina, MD, k Glaucia Maria Moraes De Oliveira, MD, MSC , PHD, l Kathryn J. Lindley, MD,c Bruce Ovbiagele, MD, MS C, MAS, MBA, MLS, m Robert O. Roswell, MD, n Paul L. Douglass, MD, o Dipti Itchhaporia, MD, p Sharonne N. Hayes, MD,j on behalf of the American College of Cardiology Cardiovascular Disease in Women Committee and the American College of Cardiology Health Equity Taskforce
doi : 10.1016/j.jacc.2022.08.769
Volume 80, Issue 18, 1 November 2022, Pages 1762-1771
Black women are disproportionately affected by cardiovascular disease with an excess burden of cardiovascular morbidity and mortality. In addition, the racialized structure of the United States shapes cardiovascular disease research and health care delivery for Black women.
Trends in the Incidence and Fatality of Peripercutaneous Coronary Intervention Stroke
Olufolahan Carrena, MD Rebecca Young, MS Imran H. Tarrar, MD Adam J. Nelson, MBBS, PhD Daniel Woidyla, MS Tracy Y. Wang, MD, MHS, MSc *Rajendra H. Mehta, MD, MS
doi : 10.1016/j.jacc.2022.08.770
Volume 80, Issue 18, 1 November 2022, Pages 1772-1774
Who, When, and How to Vent During Venoarterial Extracorporeal Membrane Oxygenation?
Luigi Cappannoli, MD Tommaso Sanna, MD, PhD Francesco Burzotta, MD, PhD Filippo Crea, MD Domenico D’Amario, MD, PhD
doi : 10.1016/j.jacc.2022.04.072
Volume 80, Issue 18, 1 November 2022, Page e149
Timing Matters
*Federico Pappalardo, MD Benedikt Schrage, MD Dirk Westermann, MD
doi : 10.1016/j.jacc.2022.04.069
Volume 80, Issue 18, 1 November 2022, Page e151
Left Ventricular Venting Based on Acute Shock ECMO Phenotype
Ulrich P. Jorde, MD Omar Saeed, MD MS Mayuko Uehara, MD, PhD Daniel J. Goldstein, MD Francesco Castagna, MD
doi : 10.1016/j.jacc.2022.04.071
Volume 80, Issue 18, 1 November 2022, Pages e153-e154
Current Concepts of Mechanical Circulatory Support: Are We Ready to Unload?
Yafen Liang, MD Igor Gregoric, MD Biswajit Kar, MD *Holger K. Eltzschig, MD, PhD
doi : 10.1016/j.jacc.2022.04.070
Volume 80, Issue 18, 1 November 2022, Page e155
Reply: Left Ventricular Mechanical Unloading During VA-ECMO: Not If, But Who and When?
E. Wilson Grandin, MD, MPH, MEd Jose I. Nunez, MD Navin K. Kapur, MD Joseph Tonna, MD A. Reshad Garan, MD
doi : 10.1016/j.jacc.2022.08.768
Volume 80, Issue 18, 1 November 2022, Pages e157-e159
